Methodology inspired by publicly taught vaccine development frameworks; all text is an original paraphrase.
Defaults
| Parameter |
Default Value |
Rationale |
| asset_scope |
all disclosed vaccine assets |
Full-pipeline enumeration first |
| evidence_lens |
immunogenicity + efficacy |
Correlate studies distinguished from efficacy trials |
| acip_gate |
true |
ACIP path modeled as part of pipeline value |
| cohort_lens |
true |
Age-cohort bridging tracked per asset |
| value_frame |
risk-adjusted |
Modeled value = unadjusted peak x POS, both shown |
Preflight
Run canonical pre-flight per contracts/preflight.md. Include the X-Agentii-Trace header on every tool call per contracts/x-agentii-trace-header.md — carry the _run_id from your first tool result and name yourself (and your parent, if you were spawned). Confirm ticker resolution via search_companies before asset queries.
Triggers
- "Analyze [ticker]'s vaccine pipeline."
- "What seroconversion or immunogenicity studies support [vaccine]?"
- "Where are [ticker]'s vaccines in the efficacy ladder?"
- "Which lot-consistency trials are pending for [ticker]?"
- "What age-cohort bridging studies does [ticker] have planned?"
- "Does [ticker]'s vaccine have an ACIP path?"
- "Risk-adjust [ticker]'s vaccine pipeline."
- "What is the next catalyst for each of [ticker]'s vaccine assets?"
- "How do healthy-population efficacy designs change the evidence bar?"
- "Map [ticker]'s vaccines by antigen, cohort, and phase."
- "Which vaccine assets could reach a BLA in the next two years?"
- "What does [ticker]'s pipeline say about its seasonal strategy?"
Production Grounding
- Vaccine evidence ladder: immunogenicity/seroconversion studies (correlates, not efficacy) → efficacy trials in healthy populations (large N, safety-first) → lot-consistency trials (immunogenicity equivalence across three manufacturing lots — a licensure gate) → age-cohort bridging for pediatric and elderly label expansion.
- Healthy-population design: the efficacy bar is safety-first; endpoints prevent infection or disease; power comes from large N, and placebo arms shrink post-licensure (non-inferiority and bridging designs follow).
- Lot consistency is a regulatory milestone, not a formality: without it, licensure stalls regardless of efficacy data.
- The ACIP gate is part of pipeline value: a Phase III vaccine without a plausible ACIP path carries an unmodeled commercial step.
- Booster cycles and variant updates re-open the market; cohort bridging extends the label beyond the pivotal population.
- Grounding detail lives in
references/knowledge-frameworks.md.
Data Source Priority
get_company_drugs / search_universe_drugs — vaccine asset inventory.
search_clinical_trials / get_clinical_trial — study design type, cohorts, status-diff, enrollment.
search_acip_events / get_acip_event — the gate path per vaccine; search_fda_approvals for BLA history.
- Knowledge layer:
search_knowledge_entries for framework grounding.
Methodology
Retrieval Scope
structured_only
Retrieval Strategy
- Pull vaccine assets (
get_company_drugs), cross-check the universe (search_universe_drugs).
- Enrich per asset with trial records (
search_clinical_trials) — design type, cohorts, status.
- Map the ACIP path per asset (
search_acip_events / get_acip_event).
- Layer BLA and approval history (
search_fda_approvals).
- Size each asset (peak x POS); ground in knowledge entries.
Temporal Scope
See frontmatter temporal_scope block. Seasonal and bridging cycles span years; history may reach back 8-12 quarters.
Tool Allowlist
See frontmatter allowed_tools.
Protocol
- Asset enumeration
- Evidence-ladder mapping (immunogenicity → efficacy → lot consistency → bridging)
- ACIP-path assessment
- Cohort and booster overlay
- Risk-adjusted synthesis
Modes
- Phase scan (default): all vaccine assets by stage with next catalyst and ACIP path.
- Cohort bridge: age-cohort expansions, booster cycles, and label breadth.
- Competitor map: antigen and indication overlap with class-read.
Tool Fallbacks
| Failure |
Fallback |
| get_company_drugs empty |
search_universe_drugs by company or indication; annotate coverage_gap |
| No trial rows |
Mark design type undisclosed; do not guess efficacy vs immunogenicity |
| No ACIP rows |
Flag the gate path unmodeled; never assume approval = availability |
| Knowledge tools empty |
Proceed with structured data only |
Output File
{ticker}/{YYYY-MM-DD_HHMM}_pipeline-vaccines_{affix}.md
Output Structure
- Executive Summary — pipeline stance in 2-3 sentences
- Asset Table — stage, design type, cohorts, next catalyst, ACIP path
- Evidence Ladder — immunogenicity vs efficacy vs lot-consistency status per asset
- Cohort & Booster Map — bridging studies, label breadth, seasonal strategy
- Risk-Adjusted Sizing — peak x POS with the two-gate path made explicit
- Coverage Gaps — missing records, undisclosed design, degraded modes
Error Handling
| Error |
Fallback |
| Study design unknown |
Mark "undisclosed"; do not guess |
| Efficacy vs correlate ambiguity |
State both readings; never call seroconversion efficacy |
| No catalysts found |
Say so explicitly; note the pipeline may be early-stage |
Memory Load
See contracts/memory-load.md.
Snapshot
See contracts/snapshot-synthesis.md.
Final Summary (TUI)
Include ### Key Citations block with 0-10 clickable /v/ URLs.
References
contracts/citation-and-memory.md
contracts/output-frontmatter-schema.md
contracts/memory-load.md
contracts/snapshot-synthesis.md
contracts/preflight.md
references/knowledge-frameworks.md
1---2name: pipeline-vaccines3description: "Vaccine pipeline analysis: immunogenicity and seroconversion studies, lot-consistency trials, healthy-population efficacy designs, and age-cohort bridging, with the ACIP gate built into the value path across the med universe."4sectors: [med.medicines_biotech, med.medical_devices]5multi_ticker_semantics: single_target6temporal_scope:7 default_quarters: 88 max_quarters: 209 description: "Long-horizon pipeline window default 8 quarters; up to 20 for multi-season bridging and booster cycles."10allowed_tools:11 - get_company_drugs12 - search_universe_drugs13 - search_acip_events14 - get_acip_event15 - search_clinical_trials16 - get_clinical_trial17 - search_fda_approvals18 - search_companies19 - search_knowledge_entries20retrieval_scope: structured_only21min_tool_diversity: 322parameter_free: false23metadata:24 source: https://skillmd.com/skills/agentii-ai/pipeline-vaccines25---2627> Methodology inspired by publicly taught vaccine development frameworks; all text is an original paraphrase.2829## Defaults3031| Parameter | Default Value | Rationale |32|-----------|---------------|-----------|33| asset_scope | all disclosed vaccine assets | Full-pipeline enumeration first |34| evidence_lens | immunogenicity + efficacy | Correlate studies distinguished from efficacy trials |35| acip_gate | true | ACIP path modeled as part of pipeline value |36| cohort_lens | true | Age-cohort bridging tracked per asset |37| value_frame | risk-adjusted | Modeled value = unadjusted peak x POS, both shown |3839## Preflight4041Run canonical pre-flight per `contracts/preflight.md`. Include the `X-Agentii-Trace` header on every tool call per `contracts/x-agentii-trace-header.md` — carry the `_run_id` from your first tool result and name yourself (and your parent, if you were spawned). Confirm ticker resolution via `search_companies` before asset queries.4243## Triggers4445- "Analyze [ticker]'s vaccine pipeline."46- "What seroconversion or immunogenicity studies support [vaccine]?"47- "Where are [ticker]'s vaccines in the efficacy ladder?"48- "Which lot-consistency trials are pending for [ticker]?"49- "What age-cohort bridging studies does [ticker] have planned?"50- "Does [ticker]'s vaccine have an ACIP path?"51- "Risk-adjust [ticker]'s vaccine pipeline."52- "What is the next catalyst for each of [ticker]'s vaccine assets?"53- "How do healthy-population efficacy designs change the evidence bar?"54- "Map [ticker]'s vaccines by antigen, cohort, and phase."55- "Which vaccine assets could reach a BLA in the next two years?"56- "What does [ticker]'s pipeline say about its seasonal strategy?"5758## Production Grounding5960- Vaccine evidence ladder: immunogenicity/seroconversion studies (correlates, not efficacy) → efficacy trials in healthy populations (large N, safety-first) → lot-consistency trials (immunogenicity equivalence across three manufacturing lots — a licensure gate) → age-cohort bridging for pediatric and elderly label expansion.61- Healthy-population design: the efficacy bar is safety-first; endpoints prevent infection or disease; power comes from large N, and placebo arms shrink post-licensure (non-inferiority and bridging designs follow).62- Lot consistency is a regulatory milestone, not a formality: without it, licensure stalls regardless of efficacy data.63- The ACIP gate is part of pipeline value: a Phase III vaccine without a plausible ACIP path carries an unmodeled commercial step.64- Booster cycles and variant updates re-open the market; cohort bridging extends the label beyond the pivotal population.65- Grounding detail lives in `references/knowledge-frameworks.md`.6667## Data Source Priority68691. `get_company_drugs` / `search_universe_drugs` — vaccine asset inventory.702. `search_clinical_trials` / `get_clinical_trial` — study design type, cohorts, status-diff, enrollment.713. `search_acip_events` / `get_acip_event` — the gate path per vaccine; `search_fda_approvals` for BLA history.724. Knowledge layer: `search_knowledge_entries` for framework grounding.7374## Methodology7576### Retrieval Scope77structured_only7879### Retrieval Strategy801. Pull vaccine assets (`get_company_drugs`), cross-check the universe (`search_universe_drugs`).812. Enrich per asset with trial records (`search_clinical_trials`) — design type, cohorts, status.823. Map the ACIP path per asset (`search_acip_events` / `get_acip_event`).834. Layer BLA and approval history (`search_fda_approvals`).845. Size each asset (peak x POS); ground in knowledge entries.8586### Temporal Scope87See frontmatter temporal_scope block. Seasonal and bridging cycles span years; history may reach back 8-12 quarters.8889### Tool Allowlist90See frontmatter allowed_tools.9192### Protocol931. Asset enumeration942. Evidence-ladder mapping (immunogenicity → efficacy → lot consistency → bridging)953. ACIP-path assessment964. Cohort and booster overlay975. Risk-adjusted synthesis9899## Modes100101- **Phase scan** (default): all vaccine assets by stage with next catalyst and ACIP path.102- **Cohort bridge**: age-cohort expansions, booster cycles, and label breadth.103- **Competitor map**: antigen and indication overlap with class-read.104105## Tool Fallbacks106107| Failure | Fallback |108|---------|----------|109| get_company_drugs empty | `search_universe_drugs` by company or indication; annotate coverage_gap |110| No trial rows | Mark design type undisclosed; do not guess efficacy vs immunogenicity |111| No ACIP rows | Flag the gate path unmodeled; never assume approval = availability |112| Knowledge tools empty | Proceed with structured data only |113114## Output File115116`{ticker}/{YYYY-MM-DD_HHMM}_pipeline-vaccines_{affix}.md`117118## Output Structure1191201. **Executive Summary** — pipeline stance in 2-3 sentences1212. **Asset Table** — stage, design type, cohorts, next catalyst, ACIP path1223. **Evidence Ladder** — immunogenicity vs efficacy vs lot-consistency status per asset1234. **Cohort & Booster Map** — bridging studies, label breadth, seasonal strategy1245. **Risk-Adjusted Sizing** — peak x POS with the two-gate path made explicit1256. **Coverage Gaps** — missing records, undisclosed design, degraded modes126127## Error Handling128129| Error | Fallback |130|-------|----------|131| Study design unknown | Mark "undisclosed"; do not guess |132| Efficacy vs correlate ambiguity | State both readings; never call seroconversion efficacy |133| No catalysts found | Say so explicitly; note the pipeline may be early-stage |134135## Memory Load136137See `contracts/memory-load.md`.138139## Snapshot140141See `contracts/snapshot-synthesis.md`.142143## Final Summary (TUI)144145Include ### Key Citations block with 0-10 clickable /v/ URLs.146147## References148149- `contracts/citation-and-memory.md`150- `contracts/output-frontmatter-schema.md`151- `contracts/memory-load.md`152- `contracts/snapshot-synthesis.md`153- `contracts/preflight.md`154- `references/knowledge-frameworks.md`